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Osteoporosis leads to significant morbidity and mortal-ity, including 250 000 hip fractures in women annual-
ly in the US.1 A minority (one-third) of these osteoporotic
women are diagnosed and even fewer (14%) receive treat-
ment. The diagnosis of osteoporosis involves physical as-
sessment, identification of risk factors, and bone mineral
density (BMD) testing. According to the World Health Or-
ganization, BMD is best expressed as a t-score, the number
of standard deviations (SD) above or below the average
bone density of young, healthy adults.2
The gold standard for BMD assessment is central dual-
energy X-ray absorptiometry (cDXA).1 Due to the high
cost of and limited access to cDXA testing, alternative
methods are available for use in the ambulatory care set-
ting for point-of-care (POC) screening. These devices, in-
cluding peripheral DXA and quantitative ultrasound (QUS),
provide portable, easy-to-operate, low-cost screening op-
tions.3-5 In previous studies, t-scores obtained from QUS
devices have been shown to correlate significantly with
cDXA.6-10 However, these correlations are modest and
their discordance from the cDXA t-scores may be due to
several factors, including the fact that measurements are
obtained at different sites with varying rates of age-related
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BACKGROUND: Quantitative ultrasound (QUS) devices provide portable, easy-to-operate, low-cost options for point-of-care
screening of bone mineral density (BMD). Community pharmacists should be aware of the precision, sensitivity, and specificity of
these devices prior to their purchase.
OBJECTIVE: To determine the precision, sensitivity, and specificity of the Achilles Express ultrasonometer compared with central
dual-energy X-ray absorptiometry (cDXA) as well as its utility as a bone density screening device in the community pharmacy
setting.
METHODS: A prospective study in a community pharmacy and outpatient ambulatory clinic was conducted with 2 groups of white
women. Group 1 participants were 25–35 years of age (young, healthy), and those in Group 2 were 45 years of age or older
(postmenopausal). BMD assessments of the spine and the nondominant wrist and hip were performed using cDXA. Assessments
of the heel were performed using the Achilles Express, a QUS device. The main outcome measures were correlation of t-scores
between cDXA and QUS measurements using the Pearson correlation test.
RESULTS: Twenty-two (30 ± 4 years of age) and 31 (55 ± 17 years of age) women were enrolled into Groups 1 and 2, respectively.
Significant correlations between QUS and hip and spine cDXA t-scores were found in both groups. Correlation coefficients for QUS
versus hip cDXA were 0.51 (95% CI 0.11 to 0.77) and 0.70 (95% CI 0.46 to 0.85) in Groups 1 and 2, respectively. Correlation
coefficients for the QUS versus spine cDXA were 0.64 (95% CI 0.31 to 0.84) and 0.60 (95% CI 0.31 to 0.79) in Groups 1 and 2,
respectively. The QUS device has a sensitivity level of 88% and specificity of 71% to detect a hip cDXA t-score of less than –1.
CONCLUSIONS: The Achilles Express ultrasonometer is a reasonable screening tool to detect low BMD in postmenopausal women.
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bone loss, differences in the manufacturer’s published nor-
mal reference populations, and the possibility that the de-
vices do not measure the same bone properties.5
Regardless of these differences, heel (os calcis) QUS
measurements have been shown to predict osteoporosis-re-
lated fractures in women.11-15 In one investigation, heel
QUS predicted hip fracture in women over 75 years of age
as well as hip cDXA did.11 Data supporting the use of QUS
to predict fracture risk in younger women are limited.
However, low QUS values in women 45–75 years of age
have predicted wrist and other osteoporosis-related frac-
tures with a level of accuracy similar to that of cDXA.12 In
a large study involving more than 200 000 postmenopausal
women over the age of 50 years, a variety of peripheral
BMD devices predicted overall fracture risk.13
Community pharmacies provide a convenient setting for
POC BMD testing. Studies have documented the impact
of community pharmacy screening programs using either
peripheral DXA or QUS POC devices.16-19 Peripheral
DXA, which requires radiation to deliver results, has creat-
ed safety concerns, causing some states to impose regula-
tory restrictions regarding its use in community pharma-
cies. The Food and Drug Administration has approved
QUS devices that provide community pharmacies with an
alternative method to screen for low BMD. Community
pharmacists should be aware of the precision, sensitivity,
and specificity of various QUS devices prior to purchase;
differences in such parameters can affect the validity of ob-
tained results and subsequent pharmacist recommenda-
tions for further patient follow-up. Of particular importance
is the fact that the screening results do not provide a high
rate of false negatives, a result that would give a patient the
impression that she is at low fracture risk when, in fact,
cDXA would reveal that she is at high risk for fracture.
The Achilles + (Lunar Corp., Madison, WI) QUS de-
vice, which has been shown to correlate with cDXA of the
hip (r = 0.80 femoral neck, p <  0.001) and spine (r = 0.67
spine, p < 0.001), requires a patient’s foot to be submerged
in a warm water bath.6 To decrease testing time and in-
crease operator convenience, the Achilles + was replaced
by the Achilles Express, which does not use a water bath.
The Achilles Express determines a stiffness index (SI) that
is expressed as a t-score to indicate the risk of osteoporotic
fracture in postmenopausal women. The SI is comparable
to BMD as measured by cDXA.20 Physicians can use the t-
score in conjunction with other risk factors to assist in the
diagnosis of osteoporosis in the same way that cDXA t-
scores can be used.20,21 Although the manufacturer reports
a strong correlation between the Achilles Express and the
Achilles + (r = 0.94), there is only one published abstract
that directly compares the Achilles Express with cDXA.22
Data from 8 patients with chronic kidney disease, who
were on prolonged corticosteroid therapy, identified a sig-
nificant correlation between the dominant and nondomi-
nant heel Achilles Express QUS results and hip cDXA (r =
0.84 and r = 0.84, respectively; p < 0.01). However, no
correlation existed between the dominant or nondominant
heel results of the Achilles Express QUS and spine cDXA
(r = 0.61 and r = 0.47, respectively; p > 0.1). 
The Achilles Express is commercially available for use
in community pharmacies as a bone density screening tool.
The objective of this study was to compare the precision,
sensitivity, and specificity of the Achilles Express device
with cDXA and determine its utility as a screening tool for
low BMD. This investigation included 2 groups of sub-
jects to determine the sensitivity and specificity of the de-
vice in women at minimal risk for low BMD (young,
healthy) and women at higher risk (postmenopausal).
Methods
This study was approved by the institutional review board and the
Radioisotope and Radiation Safety Committee of Albany Medical Col-
lege. Using a board-approved flyer, subjects were recruited from the Al-
bany College of Pharmacy faculty and staff and from an investigator’s
clinical practice site. Healthy women between the ages of 25 and 35
years were considered eligible for inclusion in Group 1 if they were not
pregnant and not taking any drugs known to affect BMD (eg, bisphos-
phonates, calcitonin, parathyroid hormone, corticosteroids). Women 45
years of age or older were considered eligible for inclusion in Group 2 if
they were postmenopausal (defined as absence of menses for >1 y or
surgical menopause). There were no drug exclusion criteria in Group 2.
The criteria for subject recruitment and target enrollment numbers (25 in
Group 1, 50 in Group 2) were chosen to replicate previously published
research involving QUS devices.6 White women were included in this
study because the QUS device utilized population data from white wom-
en to report t- and z-scores.20
Recruited subjects were referred to a private endocrinology practice to
schedule appointments for cDXA and QUS BMD assessments. After in-
formed consent was obtained, demographic information and history
(height, weight, dominant hand, medications, medical history) were col-
lected. Urine pregnancy tests were conducted in Group 1 subjects prior to
the cDXA test. One certified DXA technician performed all BMD assess-
ments of the nondominant wrist and hip (neck, trochanter) and the spine
(L1–L4) using the Delphia SL QDR series fan beam device (Hologic Inc.,
Bedford, MA) with all t-scores recorded. Osteopenia (t-score less than –1
and greater than –2.5) and osteoporosis (t-score –2.5 or less) were defined
according to diagnostic guidelines of the World Health Organization.2
Peripheral BMD measurements were assessed 3 times in each heel
using the Achilles Express QUS device. Assessments were conducted by
a single investigator to avoid introducing interobserver bias. The
Achilles Express QUS device combines broadband ultrasound attenua-
tion and speed of sound to reduce random measurement errors and pro-
vide greater precision in estimating fracture risk. Tissue attenuation was
determined by the change in ultrasound intensity measured between 2
transducers.5 The Achilles Express combines broadband ultrasound at-
tenuation and speed of sound into the SI, which is then compared with
age-matched controls to determine a t-score equivalent.20 The t-score
equivalents are reported in this study.
Statistical analyses were performed with the Minitab statistical pack-
age, release 14 (Minitab Inc., State College, PA). Descriptive statistics
are used to describe demographic data. To determine the positioning pre-
cision (repeat measurements on the same day with repositioning) of this
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device in our hands, the coefficient of variation of the SI using the 3
QUS measurements obtained from both heels was calculated. Correla-
tion coefficients (r) between QUS and cDXA measurements of the spine
and hip were determined by the Pearson correlation test, using the medi-
an of the 3 QUS readings obtained in the nondominant heel. Regression
analysis was performed using the median of the 3 QUS readings on each
of the comparisons (QUS– dominant vs DXA–hip, QUS– dominant vs
DXA–spine, QUS–nondominant vs DXA–hip, QUS–nondominant vs
DXA–spine) to determine the r2, which indicates the amount of variance
in one variable attributed to changes in a predictor variable.23 To deter-
mine the utility of QUS for screening in the community pharmacy set-
ting, the sensitivity, specificity, positive predictive value (PPV), and neg-
ative predictive value (NPV) for the QUS device to detect osteopenia in
comparison with cDXA were determined. Sensitivity and specificity
were defined as the ability of the QUS device to correctly identify pa-
tients with or without osteopenia on cDXA at the spine and hip. The
PPV and NPV were defined as the percent of patients having been cor-
rectly identified with or without osteopenia by QUS based on cDXA.
These values assess the reliability of a positive or negative QUS test. A
positive QUS test or cDXA was defined as a t-score of –1 or less, while
a negative QUS test or cDXA indicated the absence of disease with a t-
score greater than –1. For purposes of assessing risk of fracture and cal-
culating sensitivity, specificity, PPV, and NPV, the results for the non-
dominant heel were used. The dominant heel was not used since it is as-
sumed to have higher BMD values due to increased physical use
compared with the nondominant heel.3
Results
Fifty-four subjects were recruited over 7 months; how-
ever, one subject in Group 1 was excluded following a
positive urine test for pregnancy. Thus, 53 subjects com-
pleted the study, with 22 subjects in Group 1 and 31 in
Group 2. One subject in each group did not complete a
cDXA of the spine and wrist due to contraindications. Tar-
get enrollment of 25 and 50 subjects in Groups 1 and 2, re-
spectively, was not achieved due to logistical issues limit-
ing enrollment during the time in which one investigator
could serve as the QUS operator. These issues included
conflicts in scheduling and the end of recruitment upon
completion of the QUS operator’s residency program. The
positioning precision of the device in the hands of the sin-
gle operator was 5.6%, which is consistent with a previous
study investigating QUS devices (range 1.6–7.0%).6
Demographic data for the study participants are present-
ed in Table 1. In addition to the expected differences in the
mean age, there were significant differences in body mass
index, past smoking history, and use of thyroid and antire-
sorptive drug therapies. Correlation coefficients between
QUS and cDXA measurements are presented in Table 2.
Although weight has been shown to be an independent
predictor of BMD as measured by QUS, post hoc analysis
showed no correlation. Figure 1 illustrates the correlation
of QUS of the nondominant heel with spine (1a) and hip
(1b) cDXA in each group of women. The figure also
demonstrates the frequency of false positive and negative
results as they relate to osteopenia, defined with a line of
identity at a t-score of –1. Mean t-scores demonstrated for
all cDXA scans (hip, spine, wrist) as well as QUS mea-
surements (dominant, nondominant foot) in Group 1 were
significantly different (p < 0.05) from those in Group 2.
The mean ± SD cDXA t-scores in Group 1 were 0.1 ± 0.8,
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Table 1. Demographic Data of Study Participants 
Group 1 Group 2
Young, Healthy Postmenopausal
Characteristic (n = 22)a (n = 31)a
Age, y 30 ± 4 55 ± 17b
Height, in. 64 ± 2 63 ± 2.7
Weight, kg 64.41 ± 13.61 69.85 ± 9.98
Body mass index, kg/m2 24 ± 5 27 ± 4b
Postmenopause, y 10 ± 9
Current smoker 1 (5) 1 (3)
Past smoker 4 (18) 16 (52)b
Caffeine >5 cups/day 3 (14) 2 (6)
Family history, fracture 8 (36) 10 (32)
Adult fracture 2 (9) 9 (29)
Medication history
steroid (oral or inhaled) 0 2 (6)
diuretic 0 2 (6)
anticonvulsant 0 1 (3)
immunosuppressant 0 1 (3)
thyroid 0 7 (23)b
antiresorptive therapy 0 5 (16)b
hormone replacement/OC 3 (14) 10 (32)
natural estrogens 0 1 (3)
multivitamin 14 (64) 15 (48)
calcium 9 (41) 15 (48)
OC = oral contraceptive.
aResults are presented as mean ± SD or n (%).
bp < 0.05. 
Table 2. Correlation Coefficients of QUS versus cDXA of 
Hip, Spine, and Wrist
Correlation 
Coefficientsa
Parameter (95% CI)
Group 1, aged 25–35 y (n = 22)
hip 0.51 (0.11 to 0.77)
spineb 0.64 (0.31 to 0.84)
wrist 0.45 (0.03 to 0.74)
Group 2, postmenopausal, aged ≥45 y (n = 31)
hip 0.70 (0.46 to 0.85)
spine 0.60 (0.31 to 0.79)
wristc 0.65 (0.38 to 0.82)
TOTAL (N = 53)
hip 0.66 (0.48 to 0.80)
spined 0.65 (0.46 to 0.79)
wristd 0.60 (0.40 to 0.75)
BMD = bone mineral density; cDXA = central dual-energy X-ray ab-
sorptiometry; QUS = quantitative ultrasound.
ap < 0.05.
bn = 21.
cn = 30.
dn = 52.
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–0.1 ± 0.8 (n = 21), and 0.6 ± 0.9 for the hip, spine, and
wrist, respectively; in Group 2, they were –0.6 ± 1.2, –1.0
± 1.3, and 0.0 ± 1.5 (n =  30) for the hip, spine, and wrist,
respectively. The mean ± SD QUS t-scores in Group 1
were –0.2 ± 1.2 and –0.0 ± 1.2 for the nondominant and
dominant ankles, respectively, and in Group 2 were –1.1 ±
1.2 and –1.0 ± 1.3 for the nondominant and dominant an-
kles, respectively. Sensitivity, specificity, PPV, and NPV
data are presented in Table 3. 
Discussion
Similar to previous studies comparing other QUS de-
vices, our results show modest but significant correlations
of QUS with cDXA (r = 0.65 spine, r = 0.66 hip).6-10 The
Achilles + first-generation device demonstrated significant
correlations with cDXA of the spine, femoral neck, and
trochanter (r = 0.678, 0.8, 0.7, respectively).6 There are nu-
merous reasons for the lack of correlation (or discordance)
found when comparing BMD results from QUS and cDXA
devices.5
Due to this discordance, it is important for pharmacists
conducting BMD screenings to identify the sensitivity and
specificity of the device to detect osteopenia in the popula-
tion being screened. The results in Table 3 indicate that
QUS has variable rates of sensitivity and specificity in the
2 populations studied. The Achilles Express identified
postmenopausal (Group 2) patients with osteopenia of the
hip and spine with a 92% and 79% sensitivity, respectively,
and provided a low number of false negative results (pa-
tient having normal heel QUS but osteopenia on cDXA
measurements). Otherwise stated, BMD screening in post-
menopausal women with the Achilles Express would miss
approximately 1 in 10 women with osteopenia at the hip and
2 in 10 women with osteopenia at the spine. The specificity
of 63% and 59% for the hip and spine comparisons, re-
spectively, indicates that use of the Achilles Express may
lead to a 30– 40% incidence of false positive results (pa-
tients categorized with osteopenia by QUS when cDXA
does not indicate osteopenia). This could result in unneces-
sary follow-up cDXA testing. However, given the high
NPV (92% at hip), pharmacists can be confident that a
Achilles Express Ultrasonometer vs Dual-Energy X-Ray Absorptiometry
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Figure 1. Illustration of the correlation between the quantitative ultrasound of the nondominant heel versus the central DXA of the spine and of the hip in all wom-
en. DXA = dual-energy X-ray absorptiometry.
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negative QUS result for osteopenia in this population is
truly negative for disease at the hip, which incurs consider-
able morbidity and mortality.
While the data support the role of QUS in predicting
fracture risk in females over the age of 45 years,11-14 con-
cerns over its discordance with cDXA have led to recom-
mendations regarding its use for screening this population.5
The recommendations include follow-up cDXA scans for
patients with QUS-determined t-scores below –1 and for pa-
tients with QUS t-scores between +1 and –1 if significant
risk factors are present. An example of a screening tool to
evaluate fracture risk is the Simple Calculated Osteoporosis
Risk Estimation, which can be completed easily in a com-
munity pharmacy setting.24,25 This tool has been studied in
combination with QUS screening and has been shown to
improve sensitivity at the cost of lowering specificity.10
In the young, healthy population (Group 1), the sensitiv-
ity of the Achilles Express to detect osteopenia was 100%
in the spine and 80% in the hip. While 100% sensitivity
and a high NPV (negative result truly negative) are en-
couraging, caution is warranted in interpreting these re-
sults, as few of these study participants had documented
osteopenia. When the prevalence of disease is low, PPV
will decrease and NPV will rise.27 The potential exists for a
high rate of false negatives for osteopenia using QUS in a
younger population because BMD measured at peripheral
sites (heel, finger) may be greater than BMD measured at
central sites (lumbar spine) in this population.5,28 In other
words, a negative result with peripheral BMD in younger
patients, which involves measurement of primarily cortical
bone, does not rule out the existence of bone loss at central
sites, which are primarily composed of trabecular bone. 
Limitations of this study include a low rate of those with
t-scores indicating osteopenia and the relatively young age
of participants. Thus, the correlation of the QUS device
with cDXA in an older female population or those with de-
fined osteoporosis is unknown and deserves further study.
Our study had a relatively small sample size, which limited
our ability to identify substantial numbers of patients posi-
tive for the disease. This can impact the PPV and NPV re-
sults obtained.27
Conclusions
Pharmacists selecting a peripheral BMD screening de-
vice should familiarize themselves with the technology
available and the advantages and disadvantages of those
options.3-5 The Achilles Express ultrasonometer is a rea-
sonable screening tool for identifying low BMD in post-
menopausal women. However, the low rate of disease in
women under 35 years of age warrants caution regarding
the use of this device as a screening tool to identify low
BMD in a young, premenopausal population.
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EXTRACTO
TRASFONDO: Los dispositivos cuantitativos de ultrasonido (CUS) proveen
una opción fácil de operar, económica, y posible de portear para la
detección de la densidad mineral ósea (DMO) en el lugar de cuidado
(LDC). Los farmacéuticos de la comunidad deben conocer la precisión,
la sensibilidad, y la especificidad de los dispositivos CUS antes de
comprarlos.
OBJETIVO: Determinar la precisión, la sensibilidad, y la especificidad del
ultrasonómetro Achilles Express en comparación con el absorciómetro
central de energía dual por rayos-x (cDXA) y evaluar su utilidad como
dispositivo para la detección de la densidad ósea en la farmacia
comunitaria.
MÉTODOS: Se llevó a cabo un estudio prospectivo en una farmacia
comunitaria y clínica de pacientes ambulatorios en el que participaron
mujeres de raza caucásica entre las edades de 25 a 35 años (jóvenes,
saludables, grupo 1) y mujeres de raza caucásica de 45 años en adelante
(en la posmenopausia, grupo 2). Se evaluó la DMO mediante cDXA de
la muñeca no dominante, la cadera, y la vértebra. Se evaluó la DMO
mediante CUS del talón, utilizando el dispositivo Achilles Express. Las
mediciones principales de los resultados fueron la correlación de las
puntuaciones t entre el cDXA y las mediciones del CUS utilizando la
prueba de correlación de Pearson.
RESULTADOS: Se inscribieron 22 (30 ± 4 años) y 31 (55 ± 17 años) mujeres
en 2 grupos, respectivamente. Se encontraron correlaciones significativas
entre el CUS y las puntuaciones t mediante cDXA en la cadera y la
vértebra en ambos grupos. Los coeficientes de la correlación para el CUS
en comparación con el cDXA de la cadera fueron 0.51 (95% CI 0.11 a
0.77) y 0.70 (95% CI 0.46 a 0.85) en los grupos 1 y 2, respectivamente.
Los coeficientes de la correlación para el CUS en comparación con el
cDXA de la vértebra fueron 0.64 (95% CI 0.31 a 0.84) y 0.60 (9%5 CI
0.31 a 0.79) en los grupos 1 y 2, respectivamente. El dispositivo CUS
tiene una sensibilidad de 88% y una especificidad de 71% para detectar
una puntuación t mediante cDXA en la cadera menor de –1.
CONCLUSIONES: El ultrasonómetro Achilles Express es una herramienta
razonable para detectar una DMO baja en mujeres en la posmenopausia.
Rafaela Mena 
RÉSUMÉ
INTRODUCTION: Les appareils à ultrasons quantitatifs (USQ) sont
mobiles, facile à faire fonctionner, et représentent une option peu
coûteuse pour le dépistage de l’ostéoporose au point d’intervention. Les
pharmaciens en pratique communautaire devraient connaître la
précision, la sensibilité, et la spécificité de ces appareils avant leur achat.
OBJECTIF: Déterminer la précision, la sensibilité, et la spécificité de
l’appareil Achilles Express, comparer ces paramètres à ceux de
l’absorptiométrie biénergique à rayons X (ABX), et déterminer l’utilité
de l’appareil pour le dépistage de l’ostéoporose en pharmacie
communautaire.
DEVIS EXPÉRIMENTAL: Une étude prospective a été conduite chez un
groupe de femmes âgées de 25 à 35 ans (groupe témoin) et un groupe de
femmes âgées de 45 ans et plus (groupe de femmes ménopausées)
identifiées à partir d’une pharmacie communautaire et d’une clinique de
consultations externes. La densité minérale osseuse a été mesurée par
ABX au niveau du poignet non dominant, de la hanche, et de la colonne
vertébrale alors que les mesures avec l’USQ se sont faites au niveau du
talon en utilisant l’appareil Achilles Express. Les résultats des 2
appareils ont été comparés par le coefficient de corrélation de Pearson.
RÉSULTATS: Vingt-deux femmes (30 ± 4 ans) ont été inclues dans le
groupe témoin et 31 (55 ± 17 ans) dans le groupe de femmes
ménopausées. Des corrélations significatives ont été observées entre
l’USQ et la mesure par ABX de la hanche et de la colonne vertébrale.
Les coefficients de corrélations pour la hanche étaient de 0.51 (95% IC
0.11 à 0.77) pour le groupe témoin et de 0.70 (95% IC 0.46 à 0.85) pour
le groupe de femmes ménopausées. Les coefficients de corrélation pour
la colonne vertébrale étaient de 0.64 (95% IC 0.31 à 0.84) pour le groupe
témoin et de 0.60 (95% IC 0.31 à 0.79) pour le groupe de femmes
ménopausées. La sensibilité de l’appareil USQ à détecter un score de
moins de 1 à la hanche était de 88% alors que sa spécificité était de 71%.
CONCLUSIONS: L’appareil Achilles Express est d’une efficacité
raisonnable pour le dépistage de l’ostéoporose chez les femmes
ménopausées.
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